52465-26-6

Basic information

• Product Name: 2''-PROPYLACETANILIDE
• Synonyms: 2''-PROPYLACETANILIDE
• CAS NO: 52465-26-6
• Molecular Formula: C₁₁H₁₅NO
• Molecular Weight: 177.2429
• Mol File: 52465-26-6.mol

Chemical Properties

• Boiling Point: 333°C at 760 mmHg
• Flash Point: 196.9°C
• Appearance: /
• Density: 1.031g/cm³
• Vapor Pressure: 0.00014mmHg at 25°C
• Refractive Index: 1.549
• CAS DataBase Reference: 2''-PROPYLACETANILIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2''-PROPYLACETANILIDE(52465-26-6)
• EPA Substance Registry System: 2''-PROPYLACETANILIDE(52465-26-6)

Safety Data

• Hazardous Substances Data: 52465-26-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H15NO/c1-3-6-10-7-4-5-8-11(10)12-9(2)13/h4-5,7-8H,3,6H2,1-2H3,(H,12,13)

Upstream product

• 75-36-5 acetyl chloride 
• 1821-39-2 2-propylaniline 
• 108-24-7 acetic anhydride 

Downstream Products

• 285124-06-3 4-nitro-2-propyl-aniline 

Relevant articles and documents

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.

3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same

3-piperidyl-4-oxoquinazoline derivatives are provided, which is represented by the formula (I): wherein R represents an amino group or a cyclic amino group such as dibenzoazepine, each of which is substituted with a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, or the like, n is an integer of 1 to 3, R3and R4independently represents a hydrogen atom, a lower alkyl group, or the like, or a pharmaceutically acceptable salt thereof. Compounds (I) of the present invention have excellent MTP-inhibitory activity. Thus, these compounds not only inhibit formation of LDL that is a cause of arteriosclerotic diseases but also regulate TG, cholesterol, and lipoproteins such as LDL in the blood and regulate cellular lipids through regulation of MTP activity. They can also be used as a new type of preventive or therapeutic agents for hyperlipemia or arteriosclerotic diseases. Furthermore, they can be used as therapeutic or preventive agents for pancreatitis, obesity, hypercholesterolemia, and hypertriglyceridemia.